

# Impact of a Duration Bundle on Antimicrobial Use in a Pediatric Hospital

Treat the Source Course

Diana Li, Xuanqing Wang, Erin Weslander, Pharm D, BCIDP

University of Pittsburgh School of Pharmacy UPMC Children's Hospital of Pittsburgh

# INTRODUCTION


- Limiting antibiotic durations to the shortest effective duration is a strong recommendation with moderate-quality evidence in the 2016 IDSA Antimicrobial Stewardship Program (ASP) guidelines.
- Shortening the duration of antimicrobial therapy is being increasingly studied with similar clinical outcomes and decreased antibiotic exposure when compared to longer durations.
- An ASP bundle including a decrease in antimicrobial automatic stop dates from 14 days to 10 days along with a guideline for standard durations for 48 specific indications was implemented at a tertiary pediatric hospital in November 2019.

# **OBJECTIVES**

Assess the impact of this ASP initiative on patient outcomes by comparison of pre-intervention and post-intervention data.

## **METHODS**

- A set of antimicrobial duration recommendations for pediatric patients was created by CHP ASP team.
- Automatic stop dates in the Electronic Medical Record (EMR) were updated from 14 days to 10 days for all antimicrobials.
- Advertising campaigns of shortening antibiotics durations were shown on all hospital screensavers.
- **Design**: The CHP quality improvement committee approved retrospective review and prospective tracking of all patients received antimicrobial treatment for 23 indications in Nov.15 Dec.15, 2018 and Nov.15 Dec.15, 2019.
- Inclusion & Exclusion:



132 were included in

pre-intervention

data analysis

125 were included in


post-intervention

data analysis

#### **Demographics**

		Post-intervention (n=125)
Age – yr	8.0 years	7.4 years
Male sex - no. (%)	80 (58%)	68 (54%)

### Patient type



SOT= solid organ transplant, CF= cystic fibrosis

## Outcomes


Primary Outcomes	Pre-intervention (n=132)	Post-intervention (n=125)	Post - Pre	P- value		
Average Length of Stay	8.3 days	6.7 days	1.6 days	0.043		
Percent of patients with duration 10 days or more inpatient	14% (19/132)	6.4% (8/125)	7.6%	0.054		
Secondary Outcomes						
Average ratio- Actual: Recommended Duration	1.56 : 1	1.30 : 1		<0.001		
Average Total Duration	11.8 days	10.9 days	0.9 days	<0.001		

## **RESULTS**

## Statistics

- Outcomes analyses using R software
- Nominal data: chi-squared
- Continuous data: Wilcoxon Rank Sum Test
- All tests were 2- sided and p<0.05 is considered significant</li>

#### Indication



PNA= pneumonia, GU= genitourinary, SSTI= skin and soft tissue infection, BSI= blood stream infection, ENT= ear, nose, and throat, IAI= intra- abdominal infection, CNS= central nervous system

#### Balancing Measures and Inpatient Sub Analysis

Measure	Pre-intervention (n=132)	Post-intervention (n=125)	
Restarted treatment within 48 hours	3.8% (5/132)	0% (0/125)	
Readmitted within 30 days for same infection	6.8% (9/132)	6.4% (8/125)	
Avg Days Above Recommended Inpatient	2.3 days	0.5 days	
Sum of extra days inpatient	65.3 days	13.4 days (normalized)	

# **CONCLUSIONS**

- This intervention lead to a significant reduction in average length of stay per admission. The percent of patients with a duration more than 10 days inpatient did not meet statistical significance after the intervention.
- The rate of restarting antibiotics for the same indication within 48 hours and readmission rate within 30 days for the same infection were unchanged with this protocol.
- The intervention significantly reduced the secondary outcomes of the total duration of antimicrobial therapy and the ratio of actual duration compared to recommended duration.

## **FUTURE DIRECTIONS**

- Continue education of health care providers about the antimicrobial duration recommendations.
- Implement indication-specific antimicrobial automatic stop dates in EMR.
- Assess cost savings of the ASP bundle to shorten durations.

## REFERENCES

1. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis.* 2016;62(10):e51-e77.

# **DISCLOSURE**

The authors do not have any disclosure to report